PD-1/PD-L1 Pathway Study on Septic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01161745|
Recruitment Status : Completed
First Posted : July 14, 2010
Last Update Posted : July 14, 2010
|Condition or disease|
First, we will detect PD-L1 expression on PBMC of septic patients and healthy controls.
Second, blockade of PD-1/PD-L1 pathway in vitro and stimulate with some biomolecules and then analyze the PBMC function and apoptosis by flow cytometry.
Then, compare with healthy controls and find the differences.
|Study Type :||Observational|
|Actual Enrollment :||39 participants|
|Observational Model:||Case Control|
|Official Title:||PD-1/PD-L1 Pathway in T Lymphocyte Apoptosis and Monocyte Dysfunction in Septic Patients|
|Study Start Date :||December 2008|
|Actual Primary Completion Date :||February 2010|
|Actual Study Completion Date :||April 2010|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01161745
|Principal Investigator:||Xiao-ming Deng, doctor||Changhai Hospital, the Second Military Medical University|